Valuation: Marker Therapeutics, Inc.

Market Cap 14.84M 13.34M 12.45M 11.29M 21.19M 1.41B 21.32M 149M 58.36M 733M 55.72M 54.52M 2.36B P/E 2026 *
-1.5x
P/E 2027 * -1.02x
Enterprise Value 14.84M 13.34M 12.45M 11.29M 21.19M 1.41B 21.32M 149M 58.36M 733M 55.72M 54.52M 2.36B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 0.74x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-14.40%
Current month-16.80%
1 month-23.91%
3 months-38.18%
6 months-44.01%
Current year-40.26%
1 week 0.89
Extreme 0.8877
1.03
1 month 0.89
Extreme 0.8877
1.31
Current year 0.89
Extreme 0.8877
2.46
1 year 0.84
Extreme 0.84
2.46
3 years 0.81
Extreme 0.8099
6.16
5 years 0.67
Extreme 0.6706
16.2
10 years 0.67
Extreme 0.6706
135.5
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Date Insider Type Main position Quantity % Market Cap. Importance
11/17/25 Free

Chairman

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-14.40%-16.02%-73.11% 15.42M
-2.01%-7.86%+60.74%+70.97% 70.44B
+3.84%-11.02%+8.59%+57.43% 50.31B
+3.35%+1.42%+11.85%+40.01% 47.51B
+0.51%+1.51%+27.96%+31.43% 42.91B
+2.70%-3.66%+307.41%+547.01% 40.39B
+0.69%-3.44%+9.52%+96.59% 39.69B
+0.06%-2.02%+11.25%+43.27% 30.59B
-0.36%-8.39%+37.90%+1.14% 26.8B
-0.39%-6.92%-13.60%-14.40% 22.36B
Average +0.46%-6.04%+44.56%+80.03% 37.1B
Weighted average by Cap. +0.95%-4.90%+54.77%+102.68%

Financials

2026 *2027 *
Net sales 4.24M 3.81M 3.56M 3.23M 6.06M 404M 6.09M 42.71M 16.68M 210M 15.93M 15.58M 674M 20.19M 18.15M 16.94M 15.35M 28.82M 1.92B 29M 203M 79.37M 997M 75.79M 74.14M 3.21B
Net income -11.84M -10.64M -9.93M -9M -16.9M -1.13B -17M -119M -46.54M -585M -44.44M -43.48M -1.88B -18.09M -16.27M -15.18M -13.76M -25.83M -1.72B -25.99M -182M -71.13M -894M -67.92M -66.45M -2.87B
Net Debt - -
Projected Income Statement - Annual - Marker Therapeutics, Inc.
Logo Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
5
Date Price Change Volume
26-10-14 US$0.8902 -3.75% 65,813
26-10-13 US$0.9249 -8.43% 175,224
26-10-12 US$1.010 +3.95% 107,780
26-10-09 US$0.9716 +2.27% 91,220
26-10-08 US$0.9500 -8.65% 102,304
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Marker Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8902USD
Average target price
7.867USD
Spread / Average Target
+783.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Marker Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MRKR Stock